Spots Global Cancer Trial Database for resistant cancer
Every month we try and update this database with for resistant cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | NCT06347068 | Breast Cancer Relapse Resistant Cance... Triple Negative... | iC9-CAR.B7-H3 T... cyclophosphamid... fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | NCT02098343 | Platinum Sensit... | APR-246 Carboplatin and... | 18 Years - | Aprea Therapeutics | |
| Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC | NCT05718882 | Liver Cancer Hepatocellular ... Resistant Cance... | Lenvatinib Oral... | 18 Years - 75 Years | RenJi Hospital | |
| Lorlatinib Combinations in Lung Cancer | NCT04292119 | Lung Cancer Anaplastic Lymp... ROS1 Rearrangem... Relapsed Cancer MET Amplificati... Resistant Cance... NSCLC | Lorlatinib Crizotinib Binimetinib TNO155 | 18 Years - | Massachusetts General Hospital | |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | NCT06347068 | Breast Cancer Relapse Resistant Cance... Triple Negative... | iC9-CAR.B7-H3 T... cyclophosphamid... fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| 9-ING-41 in Patients With Advanced Cancers | NCT03678883 | Cancer Pancreatic Canc... Sarcoma Renal Cancer Refractory Canc... Refractory Neop... Refractory Non-... Pancreatic Aden... Resistant Cance... Neoplasm Metast... Neoplasm of Bon... Neoplasm, Breas... Neoplasm of Lun... Neoplasms,Color... Neoplasms Pancr... Malignant Gliom... Malignancies Malignancies Mu... Bone Metastases Bone Neoplasm Bone Cancer Pancreas Cancer Pancreatic Neop... Breast Neoplasm... Acute T Cell Le... | 9-ING-41 Gemcitabine - 2... Doxorubicin. Lomustine Carboplatin. Nab paclitaxel. Paclitaxel. Gemcitabine - 2... Irinotecan | 18 Years - | Actuate Therapeutics Inc. | |
| p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | NCT02098343 | Platinum Sensit... | APR-246 Carboplatin and... | 18 Years - | Aprea Therapeutics | |
| p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | NCT03268382 | High-grade Sero... | APR-246 Pegylated Lipos... | 18 Years - | Aprea Therapeutics | |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | NCT06347068 | Breast Cancer Relapse Resistant Cance... Triple Negative... | iC9-CAR.B7-H3 T... cyclophosphamid... fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
